Black Diamond Therapeutics Announces Positive Phase 2 Silevertinib Results
Nov 10 (Reuters) - Black Diamond Therapeutics Inc BDTX.O:
BLACK DIAMOND THERAPEUTICS - ANNOUNCES POSITIVE PHASE 2 SILEVERTINIB RESULTS AND FDA FEEDBACK FOR 1L EGFR-NCM NSCLC - SEC FILING
BLACK DIAMOND THERAPEUTICS - UPDATED PHASE 2 RESULTS SHOW 86% CNS-ORR IN UNTREATED BRAIN METASTASES - SEC FILING
BLACK DIAMOND THERAPEUTICS - FDA MEETING SUPPORTS PIVOTAL DEVELOPMENT AND POTENTIAL ACCELERATED APPROVAL BASED ON CNS-ORR - SEC FILING
Further company coverage: BDTX.O